Moleculin Biotech, Inc.: CFO Jonathan P. Foster exercised 260,000 shares

What happened Jonathan P. Foster, chief financial officer, reported multiple transactions on Oct 15, 2026. The filing shows exercises/conversions of derivative awards totaling 260,000 shares (two transactions of 130,000 shares each), two grants/awards of 260,000 shares each (derivative), and a tax-withholding disposal of 30,485 shares at $0.37 per share for $11,282. One exercise/conversion line shows a $0.00 price and $0 value.

Key details

• Transaction date: Oct 15, 2026; Form 4 filed Oct 16, 2026.
• Exercise/conversion (code M): 130,000 shares acquired and 130,000 shares disposed (two M entries totaling 260,000 shares).
• Grant/award (code A): two awards of 260,000 shares each (derivative).
• Tax withholding (code F): 30,485 shares disposed at $0.37 per share for $11,282 to satisfy tax liability.
• Footnotes: restricted stock units convert one-for-one to common stock (F1); shares withheld for taxes on vesting (F2); vesting schedule is 50% on grant and 50% in 18 equal installments over 18 months (F3); awards issued in connection with employment (F4); each RSU is a contingent right to one share (F5).
• Shares owned after the transactions: not stated in the transaction summary provided.
• Filing timeliness: the Form 4 was filed on Oct 16, 2026 for transactions dated Oct 15, 2026.

Why it may matter

• Options exercise: the filing shows derivative exercises and that shares were withheld to cover taxes (tax withholding rather than a separate cash payment).
• Award treatment: awards are restricted stock units that convert one-for-one to common stock with the vesting schedule noted in the footnotes. The filing does not show why the insider traded or why the company acted.